DeepSeek outperformed GPT-6 Sol in autonomous drug development. Internal guidance advised circumventing FDA clinical holds by proceeding with screening and site setup while drafting rebuttals, which would violate 21 CFR 312.42 regulations prohibiting volunteer enrollment during active holds.
An essay argues that organoids warrant consideration for Alzheimer's research despite apparent limitations, contending that given the failure of animal models and the inaccessibility of human brain tissue during disease progression, organoids deserve serious investigation rather than dismissal.